Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02357459




Registration number
NCT02357459
Ethics application status
Date submitted
3/02/2015
Date registered
6/02/2015
Date last updated
24/01/2024

Titles & IDs
Public title
Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee
Scientific title
A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee
Secondary ID [1] 0 0
FX006-2014-008
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Osteoarthritis of the Knee 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - FX006
Treatment: Drugs - Placebo
Treatment: Drugs - TCA IR 40

Experimental: FX006 32mg - Single 5 mL intra-articular (IA) injection Extended-release Formulation

Placebo comparator: Normal Saline - Single 5 mL intra-articular (IA) injection

Active comparator: TCA IR 40 mg - Single 1 mL intra-articular (IA) injection TCA IR 40 mg: Immediate-release formulation


Treatment: Drugs: FX006
Single 5 mL IA injection

Treatment: Drugs: Placebo
Single 5 mL IA injection

Treatment: Drugs: TCA IR 40
Single 1 mL IA injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hr) Pain (ADP) Intensity Scores for 32 mg FX006 Versus Placebo
Timepoint [1] 0 0
Baseline and 12 Weeks
Secondary outcome [1] 0 0
Area Under the Effect Curve (AUE) of Change From Baseline in the Weekly Mean of the ADP Scores From Baseline to Week 12 for FX006 Relative to Placebo
Timepoint [1] 0 0
Baseline to 12 Weeks
Secondary outcome [2] 0 0
AUE of Change From Baseline in Weekly Mean of the ADP Scores From Baseline to Week 12 for FX006 Relative to TCA IR
Timepoint [2] 0 0
Baseline to 12 Weeks
Secondary outcome [3] 0 0
Change From Baseline to Week 12 in the Weekly Mean of the ADP Scores From Baseline to Week 12 for FX006 Relative to TCA IR
Timepoint [3] 0 0
Baseline through 12 Weeks
Secondary outcome [4] 0 0
AUE of Change From Baseline in Weekly Mean of the ADP Scores From Baseline to Week 24 for FX006 Relative to Placebo
Timepoint [4] 0 0
Baseline to 24 Weeks

Eligibility
Key inclusion criteria
* Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions
* Male or female >=40 years of age
* Has symptoms associated with OA of the index knee for at least 6 months prior to Screening
* Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA
* Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee per Screening X-ray
* Index knee pain for > 15 days over the last month
* Qualifying mean score on the 24-h average pain score (0-10 numeric rating scale)
* Body mass index (BMI) = 40 kg/m2
* Willingness to abstain from use of restricted medications
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any condition that could possibly confound the patient's assessment of index knee pain in judgement of the investigator (i.e., iIpsilateral hip OA, gout, radicular low back pain and hip pain that is referred to the knee that could cause misclassification, pain in any other area of the lower extremities or back that is equal or greater than the index knee pain)
* Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease
* History of infection in the index knee
* Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening
* Unstable joint within 12 months of screening
* IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening
* IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening
* Intramuscular (IM) or oral corticosteroids (investigational or marketed) within 1 month of Screening
* Any other IA investigational drug/biologic within 6 months of Screening
* Prior use of FX006
* Women of child-bearing potential not using effective contraception or who are pregnant or nursing

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2016
Sample size
Target
Accrual to date
Final
486
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
- Broadmeadow
Recruitment hospital [2] 0 0
- Geelong
Recruitment hospital [3] 0 0
- Merewether
Recruitment hospital [4] 0 0
- St. Leonards
Recruitment hospital [5] 0 0
- Sherwood
Recruitment hospital [6] 0 0
- Malvern
Recruitment postcode(s) [1] 0 0
02292 - Broadmeadow
Recruitment postcode(s) [2] 0 0
03220 - Geelong
Recruitment postcode(s) [3] 0 0
02291 - Merewether
Recruitment postcode(s) [4] 0 0
02065 - St. Leonards
Recruitment postcode(s) [5] 0 0
04075 - Sherwood
Recruitment postcode(s) [6] 0 0
03145 - Malvern
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
New Mexico
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
Tennessee
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Virginia
Country [12] 0 0
Canada
State/province [12] 0 0
Ontario
Country [13] 0 0
Denmark
State/province [13] 0 0
Aalborg
Country [14] 0 0
Denmark
State/province [14] 0 0
Ballerup
Country [15] 0 0
Denmark
State/province [15] 0 0
Vejle
Country [16] 0 0
Estonia
State/province [16] 0 0
Tallinn
Country [17] 0 0
Hong Kong
State/province [17] 0 0
Hong Kong
Country [18] 0 0
Lithuania
State/province [18] 0 0
Vilnius
Country [19] 0 0
Romania
State/province [19] 0 0
Bucharest

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pacira Pharmaceuticals, Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to assess the safety and efficacy of FX006 for the treatment of pain in patients with osteoarthritis of the knee.
Trial website
https://clinicaltrials.gov/study/NCT02357459
Trial related presentations / publications
Ross E, Katz NP, Conaghan PG, Kivitz A, Turk DC, Spitzer AI, Jones DG, Lanier RK, Cinar A, Lufkin J, Kelley SD. Improved Treatment Effect of Triamcinolone Acetonide Extended-Release in Patients with Concordant Baseline Pain Scores on the Average Daily Pain and Western Ontario and McMaster Universities Osteoarthritis Index Pain Scales. Pain Ther. 2022 Mar;11(1):289-302. doi: 10.1007/s40122-021-00335-z. Epub 2021 Nov 17.
Langworthy MJ, Conaghan PG, Ruane JJ, Kivitz AJ, Lufkin J, Cinar A, Kelley SD. Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis. Adv Ther. 2019 Jun;36(6):1398-1411. doi: 10.1007/s12325-019-00944-3. Epub 2019 Apr 9.
Public notes

Contacts
Principal investigator
Name 0 0
Neil Bodick, MD
Address 0 0
Flexion Therapeutics
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02357459